Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 2/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30779643 | 1.00 | LRRK2 (0.47) | LRRK2L3MBTL1SGMS2TDP1PPIA | |
| SCHEMBL30779622 | 0.90 | LRRK2 (0.48) | LRRK2L3MBTL1SGMS2TDP1PPIA | |
| SCHEMBL21644624 | 0.90 | LRRK2 (0.48) | LRRK2L3MBTL1SGMS2TDP1PPIA | |
| SCHEMBL21644670 | 0.87 | KMT2A (0.58) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL30779626 | 0.87 | KMT2A (0.58) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL21644587 | 0.86 | SMN1; SMN2 (0.62) | LRRK2L3MBTL1SMN1; SMN2 | |
| SCHEMBL30779606 | 0.86 | SMN1; SMN2 (0.62) | LRRK2L3MBTL1SMN1; SMN2 | |
| SCHEMBL28890981 | 0.86 | LRRK2 (0.51) | LRRK2L3MBTL1SGMS2TDP1 | |
| SCHEMBL21644594 | 0.84 | NPC1 (0.57) | LRRK2L3MBTL1SGMS2TDP1SMN1; SMN2 | |
| SCHEMBL21644527 | 0.84 | LRRK2 (0.57) | LRRK2SGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479528-B2 | Heat shock protein 90 inhibitors | TAIPEI MEDICAL UNIVERSITY (TW) | 2022-10-25 | — | — | US | disclosed |
| US-20200039923-A1 | HEAT SHOCK PROTEIN 90 INHIBITORS | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-02-06 | — | — | US | disclosed |
| US-20200039923-A1 | HEAT SHOCK PROTEIN 90 INHIBITORS | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039923-A1 | HEAT SHOCK PROTEIN 90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | LRRK2 183/4885L3MBTL1 3195/4885SGMS2 3734/4885 |
| US-11479528-B2 | Heat shock protein 90 inhibitors | HSP90AB1, HSP90AB2P, HSP90AA1 | LRRK2 183/4885L3MBTL1 3195/4885SGMS2 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.